MaxLight™650 is a new Far-IR stable dye conjugate comparable to Alexa Fluor™647, DyLight™649, Cy5™ and offers better labeling efficiency, brighter imaging and increased immunodetection.
The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts.
AKT1 and the related AKT2 are activated by platelet-derived growth factor.
The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1.
It was shown that the activation occurs through phosphatidylinositol 3-kinase.
In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival.
Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery.
Applications:Suitable for use in FLISA, Western Blot and Dot Blot.
Other applications not tested.
Recommended Dilution:Dot Blot: 1:500Western Blot: 1:1000Optimal dilutions to be determined by the researcher.
Storage and Stability:Store product at 4°C in the dark.
DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid.
Dilute required amount only prior to immediate use.
Further dilutions can be made in assay buffer.
Caution: MaxLight™650 conjugates are sensitive to light.
For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Note: Applications are based on unconjugated antibody.
仕様
Size：100ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by Protein A affinity chromatography.
Form：Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight™650.
Specificity：Recognizes human AKT1 when phosphorylated at Ser473.
Isotype：IgG
Calc Applications Abbrev：DB FLISA WB
Calc Crossreactivity：Hu
Immunogen：KLH-conjugated synthetic phosphopeptide mapping to a fragment of residues surrounding S473 of human AKT1, UniProt Accession #P31749.
